Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China.
CONCLUSION: Standard utilization of ZA dominated real-world utilization of ZA for BM in Chinese patients with advanced lung cancer from cost-effectiveness perspective.
PMID: 30922074 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Cancer | Cancer & Oncology | China Health | General Medicine | Lung Cancer | Reclast | Zometa